Immune signatures in older patients with newly diagnosed multiple myeloma are associated with survival outcomes of first‐line therapy irrespective of frailty levels

Documenti analoghi

• Assessing frailty in myeloma: The pursuit of simplicity may sacrifice precision of predicting clinical outcomes
  di: Kazimierz Groen, et al.
  Pubblicazione: (2024)
• Uncovering the ultra‐frail: A distinct subgroup in non‐transplant eligible newly diagnosed patients with multiple myeloma, with an inferior clinical outcome
  di: Kazimierz Groen, et al.
  Pubblicazione: (2025)
• Stable isotope analysis on sediment V16-205
  di: van Donk, Jan
  Pubblicazione: (2003)
• Pharmacokinetic and pharmacodynamic evaluation of alternative pomalidomide dosing regimens in the treatment of multiple myeloma
  di: M. R. Seefat, et al.
  Pubblicazione: (2025)
• Preclinical evaluation of the CD38‐targeting engineered toxin body MT‐0169 against multiple myeloma
  di: Wassilis S. C. Bruins, et al.
  Pubblicazione: (2024)